Enliven Therapeutics

ELVNNasdaq United States Health Care Biotechnology: Pharmaceutical Preparations

Market cap

$4.430 B

$60.46 +0.32%

Close of 7 Aug 2026

Revenue

—

Not reported

Earnings

-$103.7M

Loss-making

Shares outstanding

73,270,761

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Pharmaceutical Preparations — ranked by market cap

All 501 →

#62VeradermicsMANE$4.78B
#63Edgewise TherapeuticsEWTX$4.68B
#64Enliven TherapeuticsELVN$4.43B
#65Parabilis MedicinesPBLS$4.15B
#66Genmab A/SGMAB$4.01B

Where these numbers come from

Share counts and financials for Enliven Therapeutics are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.